Landfar Bio-medicine Co., Ltd (SHE:000504)
China · Delayed Price · Currency is CNY 8.26
+0.30 (3.77%)
Nov 6, 2026, 9:25 AM CST
Landfar Bio-medicine Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 748.74 | 415.94 | 134.45 | 136.79 | 200.35 | 156.62 |
Revenue Growth | 496.75% | 209.37% | -1.71% | -31.72% | 27.92% | -10.79% |
Gross Profit Gross Profit Growth | 67.07 | 91.17 | 89.68 | 91.95 | 127.36 | 110.4 |
Operating Income Operating Income Growth | 4.25 | 6.53 | -15.34 | -36.59 | -12.91 | -21.94 |
Net Income Net Income Growth | 21.35 | 28.83 | -19.85 | -28.17 | -12.46 | -19.13 |
Earnings Per Share EPS Growth | 0.07 | 0.09 | -0.06 | -0.09 | -0.04 | -0.06 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Lithium Carbonate Production and Sales Lithium Carbonate Production and Sales Growth | 81.52 |
Scrap Steel Recycling, Processing and Sales Scrap Steel Recycling, Processing and Sales Growth | 206.05 |
Undistributed Undistributed Growth | 1.37 |
Sales of Biopharmaceutical Related Products Sales of Biopharmaceutical Related Products Growth | 39.18 |
Human Cell Detection and Storage Human Cell Detection and Storage Growth | 72.67 |
Energy Saving and Environmental Protection Services Energy Saving and Environmental Protection Services Growth | 15.15 |
Total Total Growth | 415.94 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 309.9 | 346.77 | 207.97 | 495.53 | 219.83 | 153.51 |
Total Debt Total Debt Growth | 190.34 | 341.24 | 24.06 | 203.87 | 236.33 | 312.29 |
Net Cash (Debt) Net Cash Growth | 119.56 | 5.53 | 183.91 | 291.66 | -16.5 | -158.79 |
Net Cash Growth | -10.44% | -97.00% | -36.94% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.37 | 0.02 | 0.56 | 0.93 | -0.05 | -0.50 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -129.33 | -115.74 | 4.79 | 36.28 | 166.38 | 107.1 |
Capital Expenditures CapEx Growth | -12.02 | -5.12 | -18.26 | -5.92 | -16.94 | -31.96 |
Free Cash Flow Free Cash Flow Growth | -141.36 | -120.85 | -13.47 | 30.36 | 149.44 | 75.14 |
Free Cash Flow Growth | - | - | - | -79.68% | 98.89% | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Gross Margin | 8.96% | 21.92% | 66.70% | 67.22% | 63.57% | 70.49% |
Operating Margin | 0.57% | 1.57% | -11.41% | -26.75% | -6.44% | -14.01% |
Pretax Margin | 0.74% | 4.74% | -15.51% | -32.68% | -10.76% | -19.30% |
Profit Margin | 2.85% | 6.93% | -14.76% | -20.59% | -6.22% | -12.21% |
FCF Margin | -18.88% | -29.06% | -10.02% | 22.19% | 74.59% | 47.97% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 124.47 | 102.46 | - | - | - | - |
P/FCF Ratio | - | - | - | 119.05 | 24.27 | 77.13 |
PS Ratio | 3.64 | 7.10 | 20.50 | 26.42 | 18.10 | 37.00 |